Estrogens and selective estrogen receptor modulators (SERMs) interact with estrogen receptor (ER) ␣ and ␤ to activate or repress gene transcription. To understand how estrogens and SERMs exert tissue-specific effects, we performed microarray analysis to determine whether ER␣ or ER␤ regulate different target genes in response to estrogens and SERMs. We prepared human U2OS osteosarcoma cells that are stably transfected with a tetracycline-inducible vector to express ER␣ or ER␤. Western blotting, immunohistochemistry, and immunoprecipitation studies confirmed that U2OS-ER␣ cells synthesized only ER␣ and that U2OS-ER␤ cells expressed exclusively ER␤. U2OS-ER␣ and U2OS-ER␤ cells were treated either with 17␤-estradiol (E 2 ), raloxifene, and tamoxifen for 18 h. Labeled cRNAs were hybridized with U95Av2 GeneChips (Affymetrix). A total of 228, 190, and 236 genes were significantly activated or repressed at least 1.74-fold in U2OS-ER␣ and U2OS-ER␤ cells by E 2 , raloxifene, and tamoxifen, respectively. Most genes regulated in ER␣ cells in response to E 2 , raloxifene, and tamoxifen were distinct from those regulated in ER␤ cells. Only 38 of the 228 (17%) genes were regulated by E 2 in both U2OS-ER␣ and U2OS-ER␤ cells. Raloxifene and tamoxifen regulated only 27% of the same genes in both the ER␣ and ER␤ cells. A subset of genes involved in bone-related activities regulated by E 2 , raloxifene, and tamoxifen were also distinct. Our results demonstrate that most genes regulated by ER␣ are distinct from those regulated by ER␤ in response to E 2 and SERMs. These results indicate that estrogens and SERMs exert tissue-specific effects by regulating unique sets of targets genes through ER␣ and ER␤.
INTRODUCTION
The decline of estrogen levels during menopause is associated with a variety of conditions, including hot flushes, mood swings, vaginal dryness, and accelerated bone loss (Johnson, 1998) . In an attempt to prevent these conditions, postmenopausal women are often treated with estrogens in the form of hormone replacement therapy (HRT) (Johnson, 1998) . Clinical trials proved that estrogens are effective at relieving menopausal symptoms and preventing osteoporosis (Writing Group for PEPI Trial, 1996; Torgerson, 2000) . The randomized, placebo-controlled Women's Health Initiative Trial confirmed that HRT decreases the risk of fractures, but it was terminated early because an increased risk of breast cancer and cardiovascular disease was observed (Writing Group for Women 's Health Initiative, 2002) .
The adverse effects of estrogens has inspired an intense pursuit to develop selective estrogen receptor modulators (SERMs) for HRT (McDonnell, 2000) , which can be taken for many years without eliciting serious side effects. Estrogens and SERMs produce their effects by binding to two estrogen receptors, ER␣ and ER␤ (Green et al., 1986; Kuiper and Gustafsson, 1997) . These drugs are classified based on their effects on target tissues. An estrogen acts as an agonist in all tissues, even though it can produce opposite effects. For example, estrogens promote breast cancer but prevent colon cancer (Writing Group for Women 's Health Initiative, 2002) . SERMs, such as tamoxifen and raloxifene, exhibit both estrogenic and antiestrogenic properties, depending on the tissue type. The antiestrogenic action of tamoxifen on breast cells has been exploited for decades to prevent recurrences of ER-positive breast tumors (Fisher et al., 1996) . Tamoxifen is also effective at preventing breast cancer in high-risk women (Fisher et al., 1998) , and it elicits beneficial estrogenic activity in the bone to prevent osteoporosis (Love et al., 1992) . In contrast, the estrogenic activity of tamoxifen in the uterus can lead to endometrial cancer (Bernstein et al., 1999) . Like tamoxifen, raloxifene prevents osteoporosis by acting as an agonist in bone (Delmas et al., 1997; Ettinger et al., 1999) and prevents breast cancer by acting as an antagonist (Cummings et al., 1999) . However, raloxifene is not associated Article published online ahead of print. Mol. Biol. Cell 10.1091/ mbc.E03-06 -0360. Article and publication date are available at www.molbiolcell.org/cgi/doi/10.1091/mbc.E03-06 -0360. □ D Online version of this article contains supplementary material.
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with an increased risk of endometrial cancer (Baker et al., 1998) . Unlike estrogens, these SERMs do not relieve hot flushes (Cohen and Lu, 2000) .
These clinical observations clearly illustrate that SERMs exert common and distinct tissue-specific effects compared with estrogens and that even different SERMs exhibit tissue selectivity. Elucidating the mechanism whereby estrogens and SERMs produce tissue-specific effects is important for designing better drugs to treat conditions associated with estrogen deficiency, such as menopausal symptoms and osteoporosis or excessive estrogen action, such as breast cancer. New paradigms have recently emerged regarding the molecular mechanism of action of estrogens and SERMs based on the discovery of coregulatory proteins (McKenna et al., 1999; McDonnell and Norris, 2002 ) that interact with ERs and structural studies of the ER ligand binding domain (LBD) (Brzozowski et al., 1997; Shiau et al., 1998; Pike et al., 1999) . Estrogen initiates transcriptional activation by inducing a conformational change of the ER LBD (Brzozowski et al., 1997; Shiau et al., 1998) . The repositioning of helix 12 by estrogens creates an activation function (AF)-2 surface that permits the binding of coactivators (Feng et al., 1998) , which facilitate the recruitment of factors that activate transcription or cause the remodeling of chromatin structure. In contrast, when SERMs bind to ER␣ the LXXML sequence in helix 12 interacts with the AF-2 surface and occludes the coactivator LXXLL recognition site (Shiau et al., 1998) . Thus, unlike estrogens, SERMs do not form a functional AF-2 surface (Brzozowski et al., 1997; Shiau et al., 1998) , which prevents the binding of coactivators required for gene activation. The important role of coregulatory proteins in producing tissue-specific effects was demonstrated by the findings that tamoxifen recruits the corepressor N-CoR in breast cells (Shang et al., 2000) , where it acts as an antagonist, but recruits the coactivator SRC-1 in endometrial cells, where it acts as an agonist (Shang and Brown, 2002) . These observations demonstrate that a major mechanism whereby estrogens and SERMs produce tissue-specific effects is by recruiting different coregulatory proteins to ERs.
Evidence derived from transient transfection experiments indicates that estrogens and SERMs also produce tissuespecific effects by differentially regulating response elements in target genes with ER␣ and ER␤. In response to estradiol (E 2 ), ER␣ is more effective than ER␤ at activating a classical estrogen response element (ERE) . In contrast, ER␤ is more effective at activating an AP-1 element with SERMs compared with ER␣ (Paech et al., 1997) . In fact, E 2 is an antagonist of SERM-mediated activation of AP-1 elements (Paech et al., 1997) . Compared with simple response elements used in reporter plasmids, it is not known whether E 2 and SERMs also exert distinct regulatory effects on native target genes of ER␣ and ER␤. Identifying target genes regulated by estrogens and SERMs is a critical first step required for subsequent characterization of the types of response elements present in ER␣ and ER␤ target genes and elucidation of the mechanisms whereby ER␣ and ER␤ regulate distinct genes in response to different ligands. In this study, we used microarray technology to compare the effects of E 2 and SERMs on global patterns of gene expression in a bone cell line stably transfected with ER␣ or ER␤. Our study indicates that estrogens and SERMs can produce tissuespecific effects by regulating different targets genes with ER␣ and ER␤.
MATERIALS AND METHODS

Materials
The U2OS (human osteosarcoma) cells stably transfected with the tet repressor, zeocin, hygromycin, TRIzol Reagent, pcDNA 6/V5-His, NuPAGE gels, SuperScript Choice System Platinum TaqDNA polymerase, and SuperScript II were purchased from Invitrogen (Carlsbad, CA). Human ER␣ and ER␤ cDNAs were obtained from P. Chambon, and J.-A. Gustafsson, respectively. Monoclonal ER␣ (ID5) antibody was obtained from DAKO (Carpinteria, CA), and monoclonal ER␤ antibodies (6A12, 14C8, and 7B10.7) were from GeneTex (San Antonio, TX). The Elite ABC kit was purchased from Vector Laboratories (Burlingame, CA). Enhanced chemiluminescence kits were obtained from Amersham Biosciences (Piscataway, NJ). RNeasy columns were manufactured by QIAGEN (Valencia, CA). The pGEM T-easy kit was obtained from Promega (Madison, WI). Human U95Av2 GeneChips, Test3 Arrays, BioArray High-Yield RNA Transcript Labeling kit, and the Microarray Suite version 5.0 software were obtained from Affymetrix (Santa Clara, CA). Oligonucleotides were synthesized by IDT Technologies (Coralville, IA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO) or as described previously ).
Cell Culture and Preparation of U2OS-ER␣ and ER␤ Stable Cell Lines
The MCF-7 breast cancer cell line was cultured in phenol-free DMEM/F-12 media containing 5% fetal bovine serum, 2 mM glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin. The U2OS cells were maintained in phenol-free DMEM/F-12 containing 5% stripped fetal bovine serum, 2 mM glutamine, 50 U/ml penicillin, 50 g/ml streptomycin, 50 g/ml hygromycin B, and 500 g/ml zeocin. The U2OS cells stably expressing the tet repressor were transfected with pcDNA 6/V5-His vector containing ER␣ or ER␤ cDNA.
Immunohistochemistry for ER␣ and ER␤
The U2OS-ER␣ and ER␤ cell lines were plated on chamber slides and treated with 1 g/ml doxycycline for 18 h to induce ER expression. The slides were fixed in neutral-buffered formalin and incubated in a microwave oven at full power for 20 min in 10 mM citrate buffer, pH 6, for antigen retrieval. After cooling, the slides were treated for 20 min with hydrogen peroxide/methanol to quench endogenous peroxidase activity. The slides were washed in phosphate-buffered saline (PBS) for 5 min, followed by a 30-min incubation at room temperature with 3% horse serum/PBS/0.3% Triton X-100. The slides were incubated overnight at 4°C with either anti-ER␣ (1:200), two mouse monoclonal ER␤s (14C8 and 7B10.7, 1:600 each), or without antibody to serve as a negative control. After washing in buffer, cells were stained with the avidin-biotin-peroxidase method (Elite ABC kit; Vector Laboratories), with diaminobenzidine as the Chromagen, followed by counterstaining with hematoxylin to visualize the nuclei.
Western Blot Analysis
Ten micrograms of total proteins from the U2OS-ER␣ and ER␤ cells were used for Western blot. The membranes were probed with anti-ER␣ (DAKO antibody, diluted 1:1500 in blocking buffer) or three monoclonal ER␤ antibodies (GeneTex) in 1:3000 in blocking buffer overnight at 4°C. Proteins were visualized using the enhanced chemiluminescence detection system. 
Estrogen Receptor Binding Assay
Microarrays and Data Analysis
The expression of ERs in the U2OS-ER␣ and ER␤ cells were induced with doxycycline in the absence or presence of 10 nM E 2 , 1 M raloxifene, or 1 M tamoxifen for 18 h. The U2OS-ER␣ or ER␤ cells were washed with PBS and then 1 ml of TRIzol was added to the cells. Total RNA was prepared according to the manufacturer's protocol. DNase-I treated RNAs were purified further using the RNeasy columns. Total RNA was used to synthesize doublestranded cDNA by using Superscript Choice System incorporating a T7 RNA polymerase promoter. Biotin-labeled antisense cRNA was prepared using the BioArray High-Yield RNA Transcript Labeling kit transcription kit using 6 g of total RNAs and the oligo-dT primer 5Ј GGCCAGTGAATTGTAATAC-GACTCACTATAGGGAGGCGG-(dT) 24 . cRNAs were purified with the RNeasy columns and then 20 g of cRNAs was fragmented at 94°C for 30 min in 40 l of 40 mM Tris-acetate, pH 8.1, 100 mM KOAc, 30 mM MgOAc. The fragmented samples (n ϭ 4 from untreated, n ϭ 4 E 2 , n ϭ 3 raloxifene, and n ϭ 3 tamoxifen) were hybridized with the Affymetrix Test3 Arrays and the human U95Av2 GeneChips and scanned at the Molecular Biology and Genomics Laboratory at San Francisco General Hospital. The data of untreated versus treated samples were analyzed using the Microarray Suite Version 5.0 with the default parameters. The comparative data generated for each treated group were analyzed further in Microsoft Excel. Genes displaying no signal change relative to controls in at least three experiments were considered insignificant and excluded from further analysis. Genes displaying either increase or decrease signal were selected for further analysis only if they had a Ϯ0.8 or Ϯ1.2 signal log ratio mean value (Ϯ1.74-and Ϯ 2.3-fold change, respectively) and were statistically significant (p Ͻ 0.05) in at least three separate experiments.
Semiquantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Real-Time RT-PCR
The U2OS cells were treated for 18 h with E 2 , raloxifene, or tamoxifen. Reverse transcription was performed in a 10-l reaction with 1 g of total RNA, 50 mM Tris-HCl, pH 8, 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, 500 M each dNTPs, 50 ng of random hexamers, and SuperScript II at 42°C 1 h. The cDNA was diluted 10-fold and then 1 l of the dilution was used in a 12.5-l PCR reaction containing 66 mM Tris-HCl, pH 9, 16 mM (NH 4 ) 2 SO 4 , 140 g/ml bovine serum albumin, 0.4 M each primer, 200 M each dNTP, 2 mM MgCl 2 , 4% glycerol, 4% dimethyl sulfoxide, and 1 U of Platinum TaqDNA polymerase. PCR was done for 94°C at 30 s, followed by cycles at 94°C for 10 s, 55-72°C 20 s, and then 72°C 30 s. Twenty-four to 36 PCR cycles were used, depending on the genes amplified. The following primers were used for PCR: ␣-anti-trypsin (␣-AT), 5Ј TGCCACCGCCATCTTCTTCC and 5Ј ACAT-GGCCCCAGCAGCTTCAGTCC; WISP-2, 5Ј AGCCCTGCGACCAACTCCAC and 5Ј GGCCGCACACCCACTCAGG; Mda-7, 5Ј TATTGTGCCCCATGCT-TCTTTACC and 5Ј CCCCACCCCAATGCTCTGTC; NKG2C, 5Ј TCCCC-GAATACAAGAACGCAGAA and 5Ј TTGGGAGAAAGAGGGTAGAAT-GAT; cDNA clone image 996282, 5Ј GCTCTCCTGGGCAGCGTTGTG and 5Ј CTCCGAGTTTATTGGGTGTTTGTT; transforming growth factor ␤3 (TGF␤3), 5Ј GGTGGTCCTGGCCCTGCTGAA and 5Ј GCTCCCGGGTGCTGTTGTAAAG; G0S2, 5Ј GCTCGCGCTGCCTCCTGCTC and 5Ј TTGCGCTTCTGGGCCAT-CATCTC; thrombin receptor, 5Ј GATCCCCGGTCATTTCTTCTC and 5Ј AC-CACCGCCGGCTTCTTGACCTTCA; and NKG2E, 5Ј TCCCCGAATACAAGA-ACGCAGAA and 5Ј TTAATTGGGAGAAAGAGGGTAGAA. Glyceraldehyde-3-phosphate dehydrogenase primers 5Ј ACCACAGTCCATGCCATCAC and 5Ј TC-CACCACCCTGTTGCTGTA were used for internal control. PCR products were loaded onto 2% agarose Tris borate-EDTA gels, and visualized by ethidium bromide staining.
Real-time RT-PCR was performed with the iQ SYBR green supermix on the Bio-Rad iCycler Thermal Cycler system. The typical temperature profile was an initial denaturation at 94°C, 3 min, followed by 40 cycles at 94°C for 10 s, 60 -64°C for 20 s, and then 72°C for 30 s. The data were collected and analyzed using the comparative threshold cycle method.
Northern Blotting
Twenty micrograms of total RNAs from untreated and 10 nM E 2 -treated doxycycline-induced U2OS-ER␣ and ER␤ cells were used for Northern blot. Keratin 19 (K19) cDNA (nt 170 -311, accession no. Y00503) was amplified by RT-PCR with primers 5Ј CGTGTCCTCCGCCCGCTTTGTGTC and 5Ј GGAG-GCCAGGCGGTCGTTGAGGTT, ligated into the pGEM vector, and verified by DNA sequencing on both strands. The cDNA insert was labeled with [ 32 P]dCTP by random priming, and 2 ϫ 10 6 cpm/ml probe was hybridized with the blot overnight at 64°C in 0.5 M Na 2 HPO 4 , 7% SDS, 1 mM EDTA, and 100 g/ml salmon sperm DNA. The blot was washed twice in 0.1ϫ SSC/0.1% SDS at 64°C for 20 min and subjected to autoradiography.
Chromatin immunoprecipitation (ChIP)
After an overnight treatment with 10 nM E 2 , the U2OS-ER␣ and ER␤ cells were fixed in 1% formaldehyde solution and washed with PBS, collected, and lysed on ice in the presence of protease inhibitors. The nuclear pellet was sonicated, and chromatin was collected by centrifugation. Extracts were precleared with protein G-Sepharose. Before adding anti-ER␣ or anti-ER␤, an aliquot of each sample was removed to use as an input for PCR. Immunoprecipitation was performed on a rocking platform at 4°C overnight, and immunocomplexes were captured by protein G-Sepharose beads and washed several times. Isolated chromatin was phenol-extracted and precipitated with ethanol. PCR was done with K19 primers 5Ј TCCAGCCTGGGTGACAGAGC and 5Ј TCCAAGTTCACCCCAACCTGA, which span the consensus ERE and half ERE in the K19 enhancer region (Choi et al., 2000) .
RESULTS
The Inducible-U2OS-ER␣ and U2OS-ER␤ Cell Lines Synthesize Exclusively ER␣ and ER␤, Respectively U2OS cells were stably transfected with a tetracycline-inducible vector to express ER␣ or ER␤. In the absence of doxycycline, the Tet repressor is bound to the Tet response elements in the cytomegalovirus promoter, preventing the transcription of the ER cDNA. Doxycycline binds to the Tet repressor, causing it to be released from the promoter, thereby allowing the cytomegalovirus promoter to drive the expression of ER␣ and ER␤.
The inducible expression of ER in the U2OS cell lines was characterized by performing Western blots, immunoprecipitation, immunohistochemistry, and receptor binding assays. The addition of doxycycline produced a timedependent accumulation of ER␣ or ER␤ protein ( Figure  1A ). There seemed to be very little, if any, "leaky" expression of ER␣ and ER␤ in the absence of doxycycline. Furthermore, no ER␤ (U2OS-ER␤, lane 7) was detected in ER␣ cells, nor was ER␣ detected in ER␤ cells (U2OS-ER␣, lane 14). Immunohistochemistry ( Figure 1B ) and immunoprecipitation ( Figure 1C ) studies confirmed that U2OS-ER␣ cells synthesized only ER␣ and that U2OS-ER␤ cells expressed exclusively ER␤. After an 18-h treatment with doxycycline, the U2OS-ER␣ and U2OS-ER␤ cell lines contained 69,000 and 54,000 receptors per cell by [ 3 H]E 2 binding studies (our unpublished data), respectively. Our results demonstrate that these cell lines can be used to identify target genes that are regulated exclusively by ER␣ or ER␤ in response to E 2 and SERMs.
Genes Regulated by ER␣ Are Distinct from Those Regulated by ER␤ in Response to E 2 and SERMs
To identify genes regulated by ER␣ and/or ER␤, the U2OS-ER␣ and U2OS-ER␤ cell lines were treated with doxycycline for 18 h to induce ER expression in the absence or presence of 10 nM E 2 , 1 M raloxifene, or 1 M tamoxifen. Total RNA was used to prepare cRNA for hybridization with human U95Av2 microarrays (Affymetrix), which contain 12,600 known genes. Six sets of comparative expression data of untreated versus each treated group were used to determine the genes regulated in ER␣ and ER␤ cells. In both U2OS-ER␣ and U2OS-ER␤ cells, a total of 228, 190, and 236 genes were activated or repressed by E 2 , raloxifene, and tamoxifen, respectively (Table 1) . Table 2 shows a partial list of the statistically significant (p Ͻ 0.05) regulated genes that had a mean Ϯ 0.8 signal log ratio value (Ϯ1.74-fold change). E 2 activated 67 genes in the U2OS-ER␣ cells and 121 in the U2OS-ER␤ cells (Table 1) . Only 34 genes were activated by E 2 in both cell lines. E 2 repressed 36 genes in U2OS-ER␣ cells and 42 genes in U2OS-ER␤ cells, whereas only four genes were repressed by E 2 in both cell lines. These findings demonstrate that only 38 of the 228 (17%) genes are regulated by both ER␣ and ER␤ with E 2 .
Raloxifene and tamoxifen activated and repressed a number of genes in the U2OS-ER␣ and U2OS-ER␤ cell lines. Similar to E 2 , the genes regulated by raloxifene or tamoxifen in U2OS-ER␣ cells were distinct from those regulated in U2OS-ER␤ cells. However, two distinguishing features occurred with SERMs compared with E 2 . First, many more genes were activated or repressed by SERMs in U2OS-ER␤ cells compared with the ER␣ cells. For example, 52 and 26 genes were induced by raloxifene and tamoxifen, respectively, in ER␤ cells, but only 10 and 21 genes were induced in ER␣ cells (Table 1) . Although 101 and 129 genes were repressed by SERMs in ER␤ cells, only 10 and 38 genes were inhibited in ER␣ cells. Second, the majority of genes regulated by SERMs in both ER␣ and ER␤ cells displayed opposing expression patterns. Raloxifene regulated 17 genes in opposite directions, whereas tamoxifen regulated 12 genes in opposite directions. For example, raloxifene activated NGK2C in the U2OS-ER␣ cells and inhibited NGK2C in the U2OS-ER␤ cells (Table 1) .
The regulation of ␣-AT, K19, WISP-2, Mda-7, NKG2C, and NKG2E by E 2 , raloxifene, or tamoxifen in the U2OS-ER␣ and ER␤ cell lines was verified by real-time PCR (Table 1) . Furthermore, the regulation of some genes by E 2 (WISP-2 and ␣-AT), raloxifene (NKG2C and 996282), and tamoxifen (NKG2E and G0S2) was dose dependent (Figure 2) . Overall, only 17-18% of the genes regulated by E 2 were also regulated by raloxifene or tamoxifen, and 37% of the genes regulated by raloxifene were also regulated by tamoxifen in both U2OS-ER␣ and ER␤ cell lines (Table 3A) . The name of all genes regulated by E 2 , tamoxifen, and raloxifene are presented as a supplementary material. We also found little overlap of genes regulated by ER␣ and ER␤ when the cutoff for regulation by E 2 and SERMs was increased to 2.3-fold (Table 3B) . These results clearly demonstrate that the majority of genes regulated by ER␣ are different from those regulated by ER␤ in response to E 2 or SERMs.
Bone-Related Genes Regulated by ER␣ Are Distinct from Those Regulated by ER␤ in Response to E 2 and SERMs
Because bone cells were used for these studies, we decided to further analyze the subset of regulated genes known to be involved in bone homeostasis or metabolism. We identified 30 genes that were differentially regulated in the ER␣ and ER␤ cells treated with E 2 or SERMs (Table 4 ). E 2 activated four bone-related genes in the ER␣ cells. Only one of these genes was also induced by raloxifene, whereas another gene was activated by tamoxifen. Two genes were activated only by E 2 , and one gene was specifically activated by raloxifene. In the ER␤ cells, a total of 16 genes were activated by all three drugs, but only one was induced by both raloxifene and tamoxifen, whereas the remaining eight, six, and one genes were uniquely activated by E 2 , raloxifene, and tamoxifen, respectively.
Seven bone genes were repressed in the ER␣ cells in response to E 2 and SERMs, but only one was inhibited by Figure 1 . Characterization of the stable U2OS-ER␣ and U2OS-ER␤ cell lines. (A) Doxycycline produces a time-dependent increase in ER␣ and ER␤. The U2OS-ER␣ (left) and U2OS-ER␤ (right) cell lines were treated with 1 g/ml doxycycline for increasing times before performing Western blots. Lanes 7 and 14 show that there is no ER␤ detectable in the U2OS-ER␣ cells and no ER␣ detectable in the U2OS-ER␤ cells, respectively. (B) Immunohistochemistry of U2OS-ER␣ and U2OS-ER␤ cells. Cells were treated with 1 g/ml doxycycline for 18 h on slides, fixed with formalin, and stained for ER␣ and ER␤ as described in MATERIALS AND METHODS. Cells labeled 1 and 5 were not induced with doxycycline. Cells labeled 2 and 6 were induced with doxycycline but did not receive primary antibody. Cells labeled 3 and 7 were induced with doxycycline and stained with anti-ER␤ and anti-ER␣, respectively. Cells labeled 4 and 8 were induced with doxycycline and stained with anti-ER␣ and anti-ER␤, respectively. (C) Immunoprecipitation of ER␣ and ER␤ in the stable cell lines. Cells were treated with 1 g/ml doxycycline for 18 h and the immunoprecipitated with anti-ER␣ (lanes 3, 4, and 7) and anti-ER␤ (lanes 2, 8, and 9). Lanes 1 and 6 show a positive control from cell lysate of U2OS-ER␣ and U2OS-ER␤ cells, respectively. All three techniques demonstrate that ER␣ is detected only in the ER␣ cells, whereas ER␤ is detected exclusively in the ER␤ cells.
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both E 2 and tamoxifen, whereas two, one, and three genes were inhibited specifically by E 2 , raloxifene, and tamoxifen, respectively. In the ER␤ cells, the three drugs repressed 11 genes, and three of these genes were commonly regulated by both SERMs. Three, two, and three genes were inhibited specifically by E 2 , raloxifene, and tamoxifen, respectively. Overall, 6 and 13 unique genes were regulated in the ER␣ and ER␤ cells, respectively, when treated with E 2 and SERMs. Thus, the U2OS-ER␣ and ER␤ cell lines displayed differential expression patterns of bone-related genes in response to E 2 , tamoxifen, and raloxifene.
The Effect of ER␣ Protein Level on Gene Expression Patterns in the U2OS-ER␣ Cell Line
To evaluate whether gene regulation patterns also occur at lower ER levels, we treated the U2OS-ER␣ cells for 18 h with 10 nM E 2 and increasing amounts of doxycycline. Immunoblotting shows that the level of ER␣ expression increased with the dose of doxycycline ( Figure 3A) . As determined by semiquantitative RT-PCR, no induction of WISP-2 mRNA was observed in cells not treated with doxycycline. In contrast, even at the lowest dose of doxycycline (0.1 g/ml), we detected an E 2 -dependent induction of WISP-2 in the U2OS-ER␣ cells ( Figure 3B, lane 7) .
We also examined the expression patterns of raloxifeneand tamoxifen-specific genes, after only a 3-h exposure to doxycycline, when the expression of ER␣ was comparatively low ( Figure 1A, lane 3) . We found that raloxifene activated TGF␤3 ( Figure 4A , lane 3), and tamoxifen activated G0S2 (lane 10) and repressed thrombin receptor (lane 15) at 3-h drug treatment by semiquantitative RT-PCR. Whereas some of the E 2 and SERM targets identified by the microarrays could be secondary, regulated by gene products induced earlier by liganded ERs, the findings that these genes are also regulated by 3 h suggest that some of the genes represent direct ER targets. Consistent with the microarray data, similar results were obtained with TGF␤3, G0S2 and thrombin receptor by real-time RT-PCR after 18-h exposure to raloxifene or tamoxifen ( Figure 4B ).
E 2 Increases K19 mRNA Expression and Recruits ER␣ and ER␤ to the K19 Gene
To establish that ERs interact directly with a regulated gene identified in the inducible cell lines, we examined the effects of E 2 on transcriptional regulation of the keratin 19 gene. This gene was chosen because the identification of a near-consensus ERE and half ERE (Choi et al., 2000) permitted us to design PCR primers spanning this Table 1 . Differential gene regulation by E 2 and SERMs in the U2OS-ER␣ and U2OS-ER␤ cell lines (A) Doxycycline-induced U2OS-ER␣ and U2OS-ER␤ cells were treated with 10 nM E 2 , 1 M raloxifene, or 1 M tamoxifen for 18 h. Microarray data obtained from human Affymetrix U95Av2 gene chips from untreated versus ligand-treated samples were analyzed using the Affymetrix Microarray Suite Version 5.0. Candidate genes displaying a statistically significant (p Ͻ 0.05) increase or decrease signal changes relative to controls in at least three experiments were further selected by a Ϯ0.8 signal log ratio mean cut-off (Ϯ1.74-fold). The numbers of genes activated or repressed in ER␣, ER␤, and both ER␣ ϩ ER␤ cell lines are shown. Asterisks (*) indicate the number of common genes regulated by SERMs in the ER␣ cells that displayed opposite expression patterns compared with ER␤ cells. Real-time RT-PCR for ␣-anti-trypsin, K19, WISP-2, Mda-7, NKG2C, and NKG2E was performed on U2OS-ER␣ and U2OS-ER␤ samples treated for 18 h with 10 nM E 2 , 1 M raloxifene, or 1 M tamoxifen. Fold-changes in the U2OS-ER␣ and U2OS-ER␤ samples were calculated relative to the untreated samples.
region for the ChIP assays. As shown by Northern blot analysis in Figure 5A , the expression of K19 was induced in U2OS-ER␣ and U2OS-ER␤ cells treated with 10 nM E 2 . To determine whether ER␣ and ER␤ are recruited to the endogenous K19 ERE enhancer, we performed ChIP assays with E 2 -treated U2OS-ER␣ and U2OS-ER␤ cells. As shown in Figure 5B , E 2 recruited ER␣ and ER␤ to the region of the endogenous K19 gene that contains the ERE enhancer. These results demonstrate that ERs can be detected at the native ERE of an estrogen-inducible gene known to be a physiological ER target.
E 2 and SERMs Increase the Expression of the Same Genes in MCF-7 Breast Cancer Cell Line
To investigate whether genes identified by microarrays are also regulated in cells not transfected with ERs, we examined the effect of the three drugs on several genes in MCF-7 breast cancer cells, which express endogenous ER␣ protein. Similar to the U2OS-ER␣ cells, E 2 also increased the expression of K19, WISP-2, and ␣-AT in MCF-7 cells ( Figure 6A ). Raloxifene also increased the expression of NKG2C and clone 996282, whereas tamoxifen increased NKG2E and G0S2 in MCF-7 cells (Figure 6 , B and C). Thus, several target genes identified by microarrays in U2OS-ER␣ cells are regulated similarly in MCF-7 cells that express endogenous ER␣.
DISCUSSION
We used microarray technology to identify genes regulated by estrogens and SERMs. Our results demonstrated that most genes regulated by E 2 and SERMs in ER␣ cells were distinct from those genes regulated in ER␤ cells. Because these results were obtained with a single time point and one concentration of each drug, it is possible that other patterns of gene regulation may occur with other treatment regimens.
In both U2OS-ER␣ and U2OS-ER␤ cell lines, we found that E 2 , raloxifene, and tamoxifen activated and repressed a total of 228, 190, and 236 genes, respectively, of the 12,600 genes on the GeneChip. Among the genes activated by E 2 were keratin 19 and WISP-2, which are known estrogen-inducible genes (Choi et al., 2000; Inadera et al., 2000) . Raloxifene increased TGF␤3, which is a known gene regulated by raloxifene in bone (Yang et al., 1996) . Most genes regulated by E 2 and SERMs in U2OS cells are novel ER targets. Importantly, the regulation of several target genes persisted even when the levels of ERs were lowered by reducing the concentration of doxycycline or by shortening the time of exposure to doxycycline to 3 h. These observations suggest that our microarray results are not due to overexpressed ERs or nonspecific squelching of transcription factors. We also showed that ER␣ and ER␤ are recruited to the ERE enhancer in the keratin 19 gene by ChIP assays. Thus, ERs interacted with a known target gene for estrogens in the stable cell lines. In addition, some regulated genes identified in the U2OS ER␣ cells were also regulated in MCF-7 cells that express endogenous ER␣. Collectively, these observations indicate that the regulated genes in U2OS cells identified by the arrays are authentic target genes. The complex pattern of gene regulation by E 2 and SERMs is surprising. Only 38 of 288 (17%) genes were commonly regulated by E 2 in U2OS-ER␣ and ER␤ cells. In comparison, 
Ϫ8
-10 Ϫ6 M tamoxifen (C). The extracted total RNA was analyzed by RT-PCR as described in MATERIALS AND METHODS. The genes examined were the WISP-2, ␣-AT, NKG2C, cDNA clone image 996282, NKG2E, and G0S2. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. The data presented were representative of at least three experiments. (Levenson et al., 2002) . Our most striking observation was that SERMs regu- Before transfer to a nylon blot and hybridization with the K19 cDNA probe (left), the gel containing ethidium bromide-stained RNAs (right) was photographed for a loading control. (B) ER␣ and ER␤ bind the ERE enhancer in the endogenous K19 gene. ChIP assays were performed using U2OS-ER␣ (left) and U2OS-ER␤ (right) cells. Anti-ER␣-and anti-ER␤-precipitated DNAs were amplified with PCR primers spanning the near consensus ERE and half ERE in the K19 enhancer region (Choi et al., 2000) . PCR products from input chromatin before and after immunoprecipitation (IP) are shown. lated some genes in opposite directions with ER␣ and ER␤. For example, NKG2C was increased by raloxifene in ER␣ cells, but repressed by raloxifene in ER␤ cells. The mechanism and functional significance whereby SERMs regulate some genes in opposite directions requires a better characterization of the promoter elements in those genes. It is unlikely that the differences in gene profiles resulted from different levels of the ER␣ and ER␤, because receptor binding assays demonstrated that the ER␣ and ER␤ cell lines contained comparable numbers of receptors. Our observation that ER␣ and ER␤ regulate different genes in response to E 2 and SERMs underscores the complexity of steroid receptor-mediated gene transcription. The complexity likely arises from presence of different types of response elements in target promoters and the differential utilization of cofactors and their regulatory surfaces by ER␣ or ER␤. Three classes of response elements have been described in gene promoters: simple, composite, and tethering. Steroid receptors bind directly and independently to simple elements such as the classic ERE, whereas they bind to DNA in conjunction with other transcription factors at composite elements. Tethering elements include AP-1, Sp1, and nuclear factor-B (Kushner et al., 2000; Abdelrahim, 2002; Tzagarakis-Foster et al., 2002) , which recruit ERs to promoters indirectly through protein-protein interactions. Multiple coregulators interact with ERs to mediate transcriptional regulation, including the p160 proteins (SRC1, GRIP1, and AIB1) (Onate et al., 1995; Hong et al., 1996; Anzick et al., 1997) , CBP/p300 (Kamei et al., 1996) , and TRAP/DRIP (Fondell et al., 1996; Rachez and Freedman, 2001) complexes. Using a factor pair analysis approach, Rogatsky et al. (2002) showed not only distinct coregulatory proteins but also different active surfaces of the same factors are being selectively engaged by the glucocorticoid receptor in different response elements contexts. The ligand also determines coregulator binding specificity. E 2 recruits coactivators, such as GRIP1 (Hong et al., 1996; McKenna et al., 1999) , whereas raloxifene and tamoxifen recruit corepressors, such as NCoR to ERs (Shang et al., 2000; Shang and Brown, 2002) . Thus, the interaction of ER␣ and ER␤ with different ligands and response elements, and their recruitment of distinct factors and cofactor surfaces may be largely responsible for the differences in gene expression profiles observed by the microarrays with estrogens and SERMs.
Clinical studies have shown that estrogens or SERMs induce distinct effects in different tissues. For example, estrogens increase the risk of breast cancer, whereas the SERMs prevent ER-positive breast tumors. Identifying the mechanisms whereby estrogens or SERMs produce tissue-specific effects is critical for developing safer drugs for preventing and treating breast cancer and conditions associated with estrogen deficiency. Our results suggest that, in addition to ligand-specific recruitment of coregulators, the relative expression of ER␣ and ER␤ in different cell types may also account for tissue-specific responses to estrogens or SERMs. Our findings indicate that estrogens and SERMs will produce a distinct phenotype in cells that express predominantly ER␣ compared with those expressing ER␤ by regulating different set of genes. Furthermore, any change in the ratio ER␣ to ER␤ in tissues that occurs with aging or disease states may alter the tissue response to estrogens or SERMs. In future studies, it will be of interest to determine whether other patterns of gene regulation occur in response to estrogens and SERMs in cells that express different ratios of ER␣ to ER␤.
Our microarray analysis has identified multiple ER␣ and ER␤ target genes regulated by E 2 and SERMs. These genes provide the groundwork necessary to characterize the different types of response elements that are present in their promoters and to determine the underlying mechanism whereby these genes are differentially regulated by ER␣ and ER␤. Understanding the mechanisms whereby ER␣ and ER␤ regulate different genes in response to estrogens and SERMs is critical for the development of more tissue-selective and safer drugs for menopausal symptoms and breast cancer. 
